DailyIQ
Last updatedUpdating…

RXRX·Recursion Pharmaceuticals Inc.

$3.74
-0.09 (-2.35%)
After Hours
High
$3.96
Open
$3.73
Market Cap
2.06B
52W High
$7.18
Low
$3.66
P. Close
$3.74
P/E
-
52W Low
$2.77
Fwd P/E
-4.25
DailyIQ Est.
$7.60
Inst. Ownership
33.3%
Short Interest
29.80%
Days to Cover
6.1
Technical Score (1D)
5
BEARISH
News Sentiment
70
BULLISH
RXRX is a momentum laggard on the 1D chart: a Technical Score of 5 with declining momentum and weak trend strength. The score ranks stocks against each other, so a reading this low says Recursion Pharmaceuticals Inc. has been one of the weaker performers in the universe, not that it is oversold. Sentiment at 70 is diverging from that weakness. $3.91 is the level a recovery would need to reclaim, and $3.53 is the next downside reference below $3.61. DailyIQ's indicator breakdown shows how individual readings such as RSI (neutral range) and MACD (bullish) look right now. Those readings are context only and do not feed the Technical Score, which ranks RXRX's momentum against the rest of the universe.
LOW TARGET
$4 +7.0%
2 analysts
MEAN TARGET
$7 +93.0%
8 analysts
HIGH TARGET
$10 +167.4%
5 analysts
PRICE RANGE
$4.00 - $10.00
SB / B / H / S / SS
2/6/5/1/1
DAILYIQ EST.
$7.60 (+103.2%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United States
Symbol
RXRX
Description
Recursion Pharmaceuticals is a clinical-stage biotechnology firm leveraging advanced technological capabilities to revolutionize drug discovery within the United States. The company's core strategy centers on decoding biological and chemical complexities through the integration of cutting-edge technologies. Recursion's pipeline features several promising drug candidates in various stages of clinical trials, including treatments for cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, and Clostridioides difficile infection, along with potential oncology therapies. Furthermore, Recursion has established strategic collaborations with prominent pharmaceutical entities and research institutions, including Bayer AG and Roche & Genentech, to advance its drug development programs. Founded in 2013 and based in Salt Lake City, Utah, Recursion is focused on transforming the drug development landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
619,507 shares
$2.2M
HERSHBERG ROBERT-
Option Exercise25,000 shares2026-10-06
HERSHBERG ROBERT-
Sell25,000 shares2026-10-06
HERSHBERG ROBERT-
Option Exercise25,000 shares2026-10-06
Borgeson Blake-
Sell50,000 shares2026-10-06
Li Dean Y-
Award/Grant3,378 shares2026-10-01
52/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-863.4%
Revenue CAGR
78.4%
Current Ratio
5.50x
Debt / Equity
0.01x
Return on Equity
-57.0%
Earnings Summary
Recursion Pharmaceuticals is a clinical‑stage biotechnology firm that leverages advanced technologies to accelerate drug discovery, operating within the broader healthcare biotechnology sector. The company’s quarterly performance has shown a gradual narrowing of losses: Q4 2024 reported a loss of $0.53 versus an estimate of $0.42 with revenue of $4.55 million; Q1 2025 loss of $0.50 versus $0.52 and revenue of $14.75 million; Q2 2025 loss of $0.41 versus $0.35 and revenue of $19.22 million; Q3 2025 loss of $0.36 versus $0.38 and revenue of $5.18 million; Q4 2025 loss of $0.21 versus $0.32 and revenue of $35.54 million; Q1 2026 loss of $0.22 versus $0.26 and revenue of $6.47 million; Q2 2026 loss of $0.25 versus $0.24 and revenue of $7.67 million. Revenue has fluctuated, peaking in Q4 2025, while EPS losses have generally narrowed, indicating incremental progress toward profitability. Historically, Recursion has consistently posted negative earnings but has shown a trend of decreasing losses and occasional revenue spikes, reflecting the impact of clinical milestones and partnership agreements. Recent news highlights several material developments: a September 28 report noted a 62.6% YoY revenue rise to $8.42 million and a projected quarterly loss of $0.24, suggesting a shift toward profitability; a data‑license extension with Tempus AI secured a three‑year commitment of $42 million, providing a steadier revenue stream; and Phase II data for REC 14881 showed rapid polyp reduction with ongoing FDA discussions, offering a potential near‑term catalyst.

EPS

EstBeatMiss
$-0.44$-0.37$-0.31$-0.24$-0.18Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$-0.23 - -
Q2'26$-0.24$-0.25-4.7%
Q1'26$-0.26$-0.22+14.4%
Q4'25$-0.32$-0.21+33.3%
Q3'25$-0.38$-0.36+5.7%
Q2'25$-0.35$-0.41-16.0%

Revenue

EstBeatMiss
$620,250$10M$20M$30M$40MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$13M - -
Q2'26$12M$8M-37.1%
Q1'26$16M$6M-59.0%
Q4'25$25M$36M+44.7%
Q3'25 - $5M -
Q2'25 - $19M -

Market Data

RXRX Stock Snapshot

BEARISH5/100
$3.74+$0.00 (0.0%)
Market cap
2.06B
Day range
$3.66 – $3.96
News sentiment
70/100 · Bullish
Analyst target
$7.22 (+93.0%)
Consensus
Buy · 15 analysts
52-week range+35.0% off low · -47.9% from high
$2.77$7.18
Price $3.74 DailyIQ Est. $7.60

RXRX's technical picture is under pressure, with momentum working against price. Position sizing matters more than usual in a name this size, where volatility is structural.

Behaviour On Record

What RXRX's own history says about today's numbers

Realized volatility (21d)
106.7% 77th pct
Below its peak
-90.6%
vs 200-day average
+9.4%
Up days (1y)
42%

Recursion Pharmaceuticals Inc. is currently running 106.7% annualised volatility over the last 21 sessions. Measured against RXRX's own 5 years of daily returns rather than a market-wide average, that is the 77th percentile — elevated for this stock, against a typical reading of 83.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RXRX is trading -90.6% below its running peak. Across 4 full years on file, its median worst-drawdown-in-a-year was -63.3%, and the deepest was -71.8% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +9.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 86th percentile — a wider gap than this stock usually carries. Over the past year RXRX closed higher on 42% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 6 years of records, RXRX finished the month higher 2 of 6 times, with a median return of -4.8% and an average of -5.9%. Its strongest month historically has been June at +8.9% on average, its weakest March at -22.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RXRX has opened more than 2% away from the prior close in 262 of 1,361 sessions (19.3% of the time), with the largest gaps running +10.6% and -18.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, RXRX moved an average of 1.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.3% and a largest of -3.0%.

All figures computed from 1,363 daily closes between 2021-04-16 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against RXRX's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RXRX's sector?

Recursion Pharmaceuticals Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, RXRX ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for RXRX?

CallsPuts

For Recursion Pharmaceuticals Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.21), with at-the-money implied volatility around 100.0%. The options market is pricing roughly a ±9.2% move by that expiry — a range of about $3.50–$4.20.

Put/call ratio (2026-10-16)
0.21
ATM implied volatility
100.0%
Total open interest
26,502
Expected move by 2026-10-16
±9.2% ($3.50–$4.20)

Analyst Rating Changes

Are analysts turning bullish or bearish on RXRX?

Morgan Stanley most recently reiterated its rating on Recursion Pharmaceuticals Inc. to Equal-Weight on May 14, 2026 with a price target of $6 (from $5). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Morgan Stanley — Equal-Weight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
May 14, 2026Morgan StanleyMaintainedEqual-Weight$5 → $6
May 7, 2026NeedhamReiteratedBuy$8
Apr 30, 2026JP MorganMaintainedOverweight$11 → $10
Feb 26, 2026B of A SecuritiesMaintainedNeutral$7 → $6
Feb 26, 2026NeedhamReiteratedBuy$8
Dec 17, 2025JP MorganUpgradeNeutral → Overweight$10 → $11
Sep 11, 2025NeedhamReiteratedBuy$8
Jul 8, 2025NeedhamReiteratedBuy$8
Jun 16, 2025Morgan StanleyMaintainedEqual-Weight$8 → $5
May 6, 2025NeedhamMaintainedBuy$11 → $8
Apr 10, 2025Morgan StanleyMaintainedEqual-Weight$10 → $8
Apr 8, 2025NeedhamReiteratedBuy$11

Peers & ETF holders

RXRX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On Oct 12, Recursion Pharmaceuticals’ stock fell more sharply than the broader market, signaling a potential short‑term weakness for the biotech firm. The decline was highlighted in a Zacks article that noted the company’s share price movement relative to market indices. The article did not provide additional context or catalysts for the drop.
What did this article say?
On October 6, Recursion Pharmaceuticals (RXRX) closed down 3.14% at $4.63, trailing the broader market. The company’s upcoming earnings were projected to report a negative EPS of $0.24, though revenue was expected to grow 62.57% year‑over‑year. Analysts noted the 31.68% monthly gain in the stock, but the negative earnings forecast tempered enthusiasm. Investors will monitor the earnings release for confirmation of the company’s financial trajectory.
What did this article say?
Cathie Wood’s ARK Invest increased its stake in Recursion Pharmaceuticals (RXRX) by purchasing approximately 1.48 million shares, worth $6.1 million, following a 16% jump in the stock on Monday. The move coincided with the announcement that RXRX has extended its data‑licensing partnership with Tempus through 2029, providing a longer‑term revenue stream. The acquisition reflects confidence in RXRX’s AI‑driven drug discovery platform and its potential to deliver future growth.
What did this article say?
Recursion Pharmaceuticals (RXRX) appeared third on a list of the most shorted stocks, with short interest at 33.5% of shares outstanding. The article noted that bearish bets exceeded 30% of shares for each of the top five names, indicating significant investor pessimism. The high short‑interest ratio suggests a substantial short side but does not confirm a price decline. The piece contextualized RXRX among other technology and biotech firms facing similar scrutiny.
What did this article say?
Recursion Pharmaceuticals (RXRX) gained 2.02% on the day, reflecting market optimism ahead of its upcoming earnings report. Analysts project a quarterly loss of $0.24 per share but highlight a 33% year‑over‑year earnings growth, while revenue is expected to climb 62.6% to $8.42 million. The company’s full‑year outlook shows a 36% earnings improvement but a 46% revenue decline, indicating mixed guidance. Investors are watching the earnings announcement for clarification on the revenue dip and potential upside catalysts.
What did this article say?
Recursion Pharmaceuticals (RXRX) and Tempus AI have extended their data‑license agreement through November 2029, shifting from up to $84 million in discretionary payments over two years to $42 million in committed payments over three years. The deal also grants Tempus a worldwide license to Recursion’s proprietary RNA‑sequencing model, potentially expanding Recursion’s data‑driven research pipeline. The agreement solidifies a long‑term partnership that could underpin future drug discovery efforts and provide a steady revenue stream for Recursion.
What did this article say?
Recursion Pharmaceuticals (RXRX) highlighted its AI‑enabled drug discovery platform and the encouraging Phase II results of REC‑4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The company plans to present additional data in November and is in discussions with the FDA about a potential registrational pathway. Partnerships with Roche/Genentech and Sanofi have already generated over $525 million in upfront payments and milestones, underscoring the commercial traction of its platform.
What did this article say?
Recursion Pharmaceuticals (RXRX) rebounded to $3.83 after a sharp daily move, yet the stock remains heavily discounted to analyst targets and fair‑value estimates. The market’s view is largely negative, with insiders expressing skepticism about the company’s prospects. The rebound appears to be short‑term momentum rather than a fundamental shift in growth outlook.
What did this article say?
Recursion Pharmaceuticals (RXRX) has published the full transcript of its second‑quarter 2026 earnings call. The company reported its Q2 financial results, but the transcript does not include new guidance or significant operational updates beyond the standard financial highlights. Investors can review the call to assess management’s commentary on pipeline progress and future outlook, though no material catalysts were disclosed. The release provides transparency but does not alter the current valuation narrative.
What did this article say?
Recursion Pharmaceuticals (RXRX) slipped 1.85% to $3.18, underperforming the broader market and the medical sector. The decline follows a prior 4.85% gain, suggesting a pullback ahead of the upcoming earnings report. Analysts project a negative EPS of $-0.24 for the quarter, with revenue expected to rise 62.6% year‑over‑year. The company’s fiscal outlook remains mixed, with a projected annual loss of $-0.92 per share and revenue of $40.32 million.

Technical Analysis

Real-time indicators across multiple timeframes

5
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $663.67M combined position · 17 adding, 8 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy47,187,7598.90%$193.00M2026-01-29
BlackRock, Inc.▲ Buy50,304,6919.49%$184.62M2026-08-07
Baillie Gifford & Co▼ Sell23,487,9074.43%$86.20M2026-08-06
Geode Capital Management, LLC▲ Buy13,819,1352.61%$50.72M2026-08-12
Norges Bank▲ Buy6,833,5341.29%$25.08M2026-08-12
Northern Trust Corp▲ Buy4,758,2360.90%$17.46M2026-08-13
Marshall Wace, LLP▲ Buy4,714,5770.89%$17.30M2026-08-13
Goldman Sachs Group Inc▼ Sell3,917,8580.74%$14.38M2026-08-14
Two Sigma Investments, LP▼ Sell3,353,6580.63%$12.31M2026-08-14
Susquehanna International Group, LLP▼ Sell3,292,1280.62%$12.08M2026-08-14
Morgan Stanley▲ Buy2,743,4990.52%$10.07M2026-08-13
Bank of America Corp▲ Buy2,597,4780.49%$9.53M2026-08-14
Millennium Management LLC▼ Sell1,834,7620.35%$6.73M2026-08-14
JPMorgan Chase & Co▼ Sell1,146,5160.22%$4.32M2026-08-12
Citigroup Inc▲ Buy864,4030.16%$3.17M2026-08-03
Invesco Ltd.▲ Buy795,6980.15%$2.92M2026-08-14
Man Group plc▼ Sell765,7860.14%$2.81M2026-08-14
Wells Fargo & Company▲ Buy510,8790.10%$1.87M2026-08-14
Verition Fund Management LLC▲ Buy446,9470.08%$1.64M2026-08-14
AQR Capital Management LLC▲ Buy422,0870.08%$1.55M2026-08-14
Schonfeld Strategic Advisors LLC▲ Buy416,8690.08%$1.53M2026-08-14
AllianceBernstein L.P.▲ Buy472,2840.09%$1.45M2026-08-14
Balyasny Asset Management L.P.▲ Buy353,6610.07%$1.30M2026-08-14
ExodusPoint Capital Management, LP▼ Sell248,7830.05%$913.0K2026-08-14
Winton Group Ltd▲ Buy192,8000.04%$707.6K2026-08-07
Q2 2026 flow:14.93M sh bought ($54.79M)5.47M sh sold ($20.11M)net +9.46M sh (+$34.68M)